Safety and efficacy of long-term outpatient ertapenem therapy

Zubair A. Qureshi, Alveena Syed, Yohei Doi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Ertapenem is increasingly utilized in outpatient parenteral antimicrobial therapy (OPAT), but data regarding the efficacy and safety of long-term ertapenem therapy have been limited. We conducted a retrospective cohort study of adult patients who received outpatient ertapenem therapy at our center between 2010 and 2013. Among 306 unique patients who were discharged on ertapenem therapy, the most common indications were intra-Abdominal infections (38%), followed by pneumonia (12%), bone and joint infections (11%), bloodstream infections (10%), urinary tract infections (10%), surgical site infections (5%), and skin and soft-tissue infections (4%). Of these 306 patients, 68 received regular outpatient follow-up visits at our infectious disease clinic, where the majority of patients (91%) were successfully treated with ertapenem by the end of therapy. Of the 6 patients who experienced clinical failure, 2 had adverse events leading to discontinuation of therapy and 4 required additional source control for clinical success. In addition, 2 patients had recurrent infection at 6 months.

Original languageEnglish
Pages (from-to)3437-3440
Number of pages4
JournalAntimicrobial agents and chemotherapy
Volume58
Issue number6
DOIs
Publication statusPublished - 01-01-2014

Fingerprint

Outpatients
Safety
Therapeutics
Infection
Intraabdominal Infections
Surgical Wound Infection
Soft Tissue Infections
Urinary Tract Infections
Communicable Diseases
ertapenem
Pneumonia
Cohort Studies
Retrospective Studies
Joints
Bone and Bones
Skin

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Qureshi, Zubair A. ; Syed, Alveena ; Doi, Yohei. / Safety and efficacy of long-term outpatient ertapenem therapy. In: Antimicrobial agents and chemotherapy. 2014 ; Vol. 58, No. 6. pp. 3437-3440.
@article{6939a73a71784e3da2dbfbbc54609cd5,
title = "Safety and efficacy of long-term outpatient ertapenem therapy",
abstract = "Ertapenem is increasingly utilized in outpatient parenteral antimicrobial therapy (OPAT), but data regarding the efficacy and safety of long-term ertapenem therapy have been limited. We conducted a retrospective cohort study of adult patients who received outpatient ertapenem therapy at our center between 2010 and 2013. Among 306 unique patients who were discharged on ertapenem therapy, the most common indications were intra-Abdominal infections (38{\%}), followed by pneumonia (12{\%}), bone and joint infections (11{\%}), bloodstream infections (10{\%}), urinary tract infections (10{\%}), surgical site infections (5{\%}), and skin and soft-tissue infections (4{\%}). Of these 306 patients, 68 received regular outpatient follow-up visits at our infectious disease clinic, where the majority of patients (91{\%}) were successfully treated with ertapenem by the end of therapy. Of the 6 patients who experienced clinical failure, 2 had adverse events leading to discontinuation of therapy and 4 required additional source control for clinical success. In addition, 2 patients had recurrent infection at 6 months.",
author = "Qureshi, {Zubair A.} and Alveena Syed and Yohei Doi",
year = "2014",
month = "1",
day = "1",
doi = "10.1128/AAC.02721-14",
language = "English",
volume = "58",
pages = "3437--3440",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

Safety and efficacy of long-term outpatient ertapenem therapy. / Qureshi, Zubair A.; Syed, Alveena; Doi, Yohei.

In: Antimicrobial agents and chemotherapy, Vol. 58, No. 6, 01.01.2014, p. 3437-3440.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety and efficacy of long-term outpatient ertapenem therapy

AU - Qureshi, Zubair A.

AU - Syed, Alveena

AU - Doi, Yohei

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Ertapenem is increasingly utilized in outpatient parenteral antimicrobial therapy (OPAT), but data regarding the efficacy and safety of long-term ertapenem therapy have been limited. We conducted a retrospective cohort study of adult patients who received outpatient ertapenem therapy at our center between 2010 and 2013. Among 306 unique patients who were discharged on ertapenem therapy, the most common indications were intra-Abdominal infections (38%), followed by pneumonia (12%), bone and joint infections (11%), bloodstream infections (10%), urinary tract infections (10%), surgical site infections (5%), and skin and soft-tissue infections (4%). Of these 306 patients, 68 received regular outpatient follow-up visits at our infectious disease clinic, where the majority of patients (91%) were successfully treated with ertapenem by the end of therapy. Of the 6 patients who experienced clinical failure, 2 had adverse events leading to discontinuation of therapy and 4 required additional source control for clinical success. In addition, 2 patients had recurrent infection at 6 months.

AB - Ertapenem is increasingly utilized in outpatient parenteral antimicrobial therapy (OPAT), but data regarding the efficacy and safety of long-term ertapenem therapy have been limited. We conducted a retrospective cohort study of adult patients who received outpatient ertapenem therapy at our center between 2010 and 2013. Among 306 unique patients who were discharged on ertapenem therapy, the most common indications were intra-Abdominal infections (38%), followed by pneumonia (12%), bone and joint infections (11%), bloodstream infections (10%), urinary tract infections (10%), surgical site infections (5%), and skin and soft-tissue infections (4%). Of these 306 patients, 68 received regular outpatient follow-up visits at our infectious disease clinic, where the majority of patients (91%) were successfully treated with ertapenem by the end of therapy. Of the 6 patients who experienced clinical failure, 2 had adverse events leading to discontinuation of therapy and 4 required additional source control for clinical success. In addition, 2 patients had recurrent infection at 6 months.

UR - http://www.scopus.com/inward/record.url?scp=84901268347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901268347&partnerID=8YFLogxK

U2 - 10.1128/AAC.02721-14

DO - 10.1128/AAC.02721-14

M3 - Article

C2 - 24709258

AN - SCOPUS:84901268347

VL - 58

SP - 3437

EP - 3440

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -